Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
|
|
- Naomi O’Neal’
- 5 years ago
- Views:
Transcription
1 1 Supplementary Online Content Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. doi: /jama etable 1. Study Inclusion and Exclusion Criteria etable 2. Changes in Atrial Fibrillation Severity Scores (AFSS) at and 3 Months efigure 1. Complete Anthropometric Data and Use of Antihypertensives and Antiarrhythmic Agents Between the Study Groups efigure 2. Changes in Primary (AFSS Symptom Burden and Symptom Severity Scores) and Secondary Outcomes (AFSS Symptom Frequency, Symptom Duration and Global Episode Severity Scores), Between the 2 Groups etable 3. Sensitivity Analysis for the Primary Outcomes Following the Exclusion of Control Subjects Who Underwent an AF Ablation etable 4. Complete Structural Data for the Control and Intervention Study Subjects efigure 3. Outline of Obstructive Sleep Apnea Management in Each Study Group etable 5. Descriptive Comparisons Between the Retained and Dropout Study Subjects etable 6. Descriptive Comparison of Control and Intervention Subjects Who Dropped Out efigure 4. Propensity Score Analysis: Propensity Score Adjusted Outcomes, I: AFSS Symptom Burden Score and AFSS Symptom Severity Score
2 efigure 5. Propensity Score Analysis: Propensity Score Adjusted Outcomes, II: Secondary (Holter Data) and Post Hoc (AFSS) Analysis etable 7. Adverse Events Documented During the Study efigure 6. Sensitivity Analyses efigure 7. Imputation Analysis (I) for Subjects Undergoing AF Ablation (Return-to- Method) efigure 8. Imputation Analysis (II) for Subjects Undergoing AF Ablation (Last Observation Method) efigure 9. Atrial Fibrillation Severity Score (AFSS) Algorithm efigure 10. Mixed-Effects Models Analysis of Residuals I and II 36
3 37 etable 1. Study Inclusion and Exclusion Criteria Inclusion Criteria Patients years of age Exclusion Criteria Serious underlying medical disorder: e.g. malignancy, chronic uncontrolled autoimmune or inflammatory disorder. Patients with paroxysmal or persistent AF, in sinus rhythm at the time of recruitment Serious underlying psychiatric disorder: e.g. eating disorder, severe psychotic disorder with recent (3 month) hospitalization or psychiatric illness requiring supervised care precluding full independent function. Patients unable to provide informed consent. Recent weight loss program participation: Recent (3 month) participation in a weight loss program, either commercial or medically supervised. Gastrointestinal malabsorption disorder: A previously diagnosed gastrointestinal malabsorption disorder interfering with macro or micronutrient absorption. Unstable INR: Elevated INR (supra-therapeutic INR and concomitant bleeding or elevated INR requiring hospitalization for pharmacological reversal administration). Persistently sub therapeutic INR (<2.0 for 14 consecutive days) in a patient with a CHADS 2 thromboembolic risk score 2. The presence of diabetes mellitus (either autoimmune or adult-onset), necessitating insulin therapy. Moderate or severe cardiac valvular lesion (stenosis or regurgitation) on echocardiography or valvular lesion requiring intervention. Diagnosed endocrinopathy: Including subclinical thyroid disease (isolated abnormal serum thyrotropin levels)
4 etable 1 (Continued) Inclusion Criteria Exclusion Criteria Age >75 years or <18 years or women of childbearing age. Active gout or history of recurrent gout in the absence of prophylactic therapy. Previous or active gallbladder disease etable 1: Study recruitment inclusion and exclusion criteria. CHADS 2 specifies the composite thromboembolic risk in AF where C is cardiac failure (1), H is hypertension (1), A is age >75 (1), D is diabetes (1) and S is stroke or TIA (2). 42
5 43 44 etable 2. Changes in Atrial Fibrillation Severity Scores (AFSS) at and 3 Months Variable Stage Control Treatment P-value ( ) ( ) AFSS Symptom burden months ( ) ( ) AFSS Frequency 7.33 ( ) 7.09 ( ) months 7.06 ( ) 6.66 ( ) 7.37 ( ) 7.08 ( ) AFSS Duration months 7.27 ( ) 6.38 ( ) 6.90 ( ) 6.84 ( ) AFSS Global episode severity months 6.69 ( ) 6.59 ( ) ( ) ( ) AFSS Symptom severity months ( ) ( ) etable 2: Data presented as mean and 95% confidence interval. The P value represents the significance of the group-time interaction derived from the mixed effects model. AFSS Atrial fibrillation Severity Score. 47
6 efigure 1. Complete Anthropometric Data and Use of Antihypertensives and Antiarrhythmic Agents Between the Study Groups (cm ) efigure 1: Shown is the decrease in waist circumference (cm), body weight (kg) and body mass index (kgm -2 ) from baseline (enrolment), to 15 months follow-up, at each 3 month time point. Also shown is the number of antihypertensive and antiarrhythmic agents used over the study duration in each group. Shown below each graph is the number of subjects in each group at each time point. Data presented as mean and 95% confidence interval (CI).
7 efigure 2. Changes in Primary (AFSS Symptom Burden and Symptom Severity Scores) and Secondary Outcomes (AFSS Symptom Frequency, Symptom Duration and Global Episode Severity Scores), Between the 2 Groups efigure 2: Changes in Atrial Fibrillation Severity Score (AFSS) components between the 2 study groups, over the study followup duration. The primary outcomes of AF symptom burden and AF symptom severity score are shown (mean and 95% CI). Secondary analysis shows the 3 burden components of symptom frequency, symptom duration and episode global severity scores. Data shown as mean and 95% CI.
8 68 69 etable 3. Sensitivity Analysis for the Primary Outcomes Following the Exclusion of Control Subjects Who Underwent an AF Ablation Outcome Control (n=61) Treatment (n=75) P-value for betweengroup comparison P-value for group-time interaction AFSS Symptom burden Follow-up 21.8 ( ) 18.6 ( ) 20.5 ( ) 8.8 ( ) 0.4 AFSS Symptom severity Follow-up 16.3 ( ) 13.6 ( ) 15.5 ( ) 6.7 ( ) 0.3 AFSS Symptom frequency Follow-up 7.4 ( ) 6.5 ( ) 6.9 ( ) 3.3 ( ) 0.4 AFSS Symptom duration Follow-up 7.4 ( ) 6.3 ( ) 6.9 ( ) 2.4 ( ) 0.4 AFSS Episode severity Follow-up 7.0 ( ) 5.8 ( ) 6.7 ( ) 3.1 ( ) 0.7 Any AF on rhythm monitor Follow-up 31 (62%) 26 (57%) 46 (66%) 16 (23%) AF episodes on rhythm monitor Follow-up AF duration on rhythm monitor (min.) Follow-up 2.84 ( ) 2.04 ( ) 1394 ( ) 1546 ( ) 3.11 ( ) 0.60 ( ) 1176 ( ) 491 ( ) 0.2 etable 3: Sensitivity analysis. It is conceivable that subjects with a greater AF symptom burden and/or a greater arrhythmia recording burden may have undergone an ablation procedure preferentially. Their censorship may therefore potentially confound the observed group differences in the study results. This sensitivity analysis shown provides a conservative estimate of the treatment effect, by exclusion of control subjects who have undergone an ablation procedure. Re-analysis of the remaining subjects does not alter the observed study results with respect to the primary and secondary outcomes. Data shown as mean and 95% CI. AFSS, Atrial Fibrillation Severity Score.
9 etable 4. Complete Structural Data for the Control and Intervention Study Subjects BASELINE FOLLOW-UP Echo parameter CONTROL (75) INTERVENTION (75) CONTROL (52) INTERVENTION (57) P LA area indexed (cm 2 m -1 ) 14.0 ( ) 13.5 ( ) 12.9 ( ) 11.5 ( ) 0.02 LA volume indexed (mlm -1 ) 41.5 ( ) 39.4 ( ) 37.7 ( ) 34.3 ( ) 0.20 Posterior wall thickness (mm) 10.1 ( ) 10.3 ( ) 9.8 ( ) 9.2 ( ) Septal wall thickness (mm) 11.5 ( ) 11.3 ( ) 10.8 ( ) 10.2 ( ) 0.01 LVEDD (mm) 48 (47-49) 48 (47-49) 48 (46-49) 46 (45-47) 0.04 Myocardial mass indexed (gm -1 ) 1.2 ( ) 1.1 ( ) 1.1 ( ) 0.9 ( ) <0.01 A wave (ms.) 52.5 ( ) 54.9 ( ) 51.5 ( ) 57.1 ( ) 0.20 E wave (ms.) 73.2 ( ) 72.5 ( ) 79.1 ( ) 72.3 ( ) 0.10 E/A ratio 1.5 ( ) 1.4 ( ) 1.6 ( ) 1.4 ( ) 0.62 E deceleration time (ms.) ( ) ( ) ( ) ( ) 0.65 E (ms.) 6.4 ( ) 6.6 ( ) 7.1 ( ) 7.1 ( ) 0.32 E/E ( ) ( ) ( ) ( ) etable 4: Group-time interaction. LA area, LA volume and myocardial mass are indexed to body height. LA left atrium, LVEDD left ventricular end-diastolic diameter. Data presented as mean and 95% confidence interval (CI). 0.55
10 85 efigure 3. Outline of Obstructive Sleep Apnea Management in Each Study Group efigure 3: Conservative therapy includes either oral appliances or positional therapy. Patients not receiving either CPAP or conservative therapy (other than weight loss) were considered untreated. OSA obstructive sleep apnea, CPAP continuous positive airways pressure.
11 etable 5. Descriptive Comparisons Between the Retained and Dropout Study Subjects Characteristic Retained Drop-outs (n=109) (n=41) P-value Age (years) ( ) ( ) 0.2 Female, n (%) 38 (35) 11 (27) 0.35 Waist circumference (cm) ( ) ( ) 0.6 Weight (kg) ( ) ( ) 0.2 BMI (kg/m ) ( ) ( ) 0.4 BSA (m ) ( ) ( ) 0.2 Blood glucose (mg/dl) ( ) ( ) 0.8 Triglyceride (mg/dl) ( ) ( ) 0.09 Total cholesterol (mg/dl) ( ) ( ) 0.7 HDL (mg/dl) ( ) ( ) 0.3 LDL (mg/dl) ( ) ( ) 0.6 C-reactive protein (mg/l) ( ) ( ) 0.02 Duration of AF (months) ( ) ( ) 0.4 Longest episode of AF (hours) ( ) ( ) 0.8 Paroxysmal AF, n (%) 109 (73) 41 (27) 0.9 AFSS - Episode frequency ( ) ( ) 0.2 AFSS - Episode duration ( ) ( ) 0.8 AFSS - Episode severity ( ) ( ) 0.6 AFSS - Burden ( ) ( ) 0.4 AFSS - symptom severity subscale ( ) ( ) 0.7 No. antiarrhythmic drugs, n (%) (62.5) 3 (37.5) 1 60 (73) 22 (27) 2 44 (73) 16 (27) No. antihypertensive drugs, n (%) (72) 8 (28) 1 46 (72) 18 (28) 2 24 (71) 10 (29) 3 13 (81) 3 (19) 4 5 (71) 2 (29) Tobacco use, n (%) 0.8 Never 62 (70) 26 (30) Current 5 (71) 2 (29) Reformed 42 (76) 13 (24)
12 etable 5: Descriptive comparisons between the retained and drop-out study subjects (continued) CPAP use, n (%) Yes 10 (83) 2 (17) Characteristic Retained Drop-outs (n=109) (n=41) No 98 (73) 37 (27) 0.5 P-value OSA, n (%) 0.4 Absent 15 (88) 2 (12) Mild 34 (76) 11 (24) Moderate 22 (67) 11 (33) Severe 24 (77) 7 (23) Hypertension, n (%) 0.8 Absent 13 (68) 6 (32) Present 96 (73) 35 (27) SBP (mmhg) ( ) ( ) 0.9 DBP (mmhg) (81-85) (82-87) 0.3 Diabetes mellitus, n (%) 0.5 Absent 75 (71) 31 (29) Present 34 (77) 10 (23) Metformin use, n (%) 1.0 Absent 107 (73) 40 (27) Present 2 (67) 1 (33) Oral hypoglycemic use, n (%) 1.0 Absent 107 (73) 40 (27) Present 2 (67) 1 (33) Alcohol consumption, n (%) Absent 65 (67) 32 (33) Present 44 (83) 9 (17) Lipid-lowering therapy use, n (%) Absent 79 (71) 32 (29) Present 30 (77) 9 (23) etable 5: Shown is descriptive data comparing the baseline characteristics of patients who completed the study and patients who did not. P values were derived from Fisher s exact test or analysis of variance. The groups were well matched with respect to all variables, except; serum C-reactive protein (greater in the retained population as compared to the drop-outs) and the consumption of 30g alcohol per week (greater in the retained population as compared to the drop-outs). BMI body mass index, BSA body surface area, HDL high density lipoprotein, LDL low density lipoprotein, AFSS Atrial Fibrillation Severity Score, CPAP continuous positive airways pressure, OSA obstructive sleep apnea, SBP systolic blood pressure, DBP diastolic blood pressure. Continuous data is shown as mean and 95% CI. Proportional data is shown as number (No.) and %
13 etable 6. Descriptive Comparison of Control and Intervention Subjects Who Dropped Out Characteristic Control Treatment (n=23) (n=18) P-value Age (years) ( ) ( ) 0.2 Female, n (%) 16 (53) 14 (47) 0.7 Waist circumference (cm) ( ) ( ) 0.5 Weight (kg) ( ) ( ) 0.5 BMI (kg/m ) ( ) ( ) 0.9 BSA (m ) ( ) ( ) 0.5 Blood glucose (mg/dl) ( ) ( ) 0.3 Triglyceride (mg/dl) ( ) ( ) 0.5 Total cholesterol (mg/dl) ( ) ( ) 0.05 HDL (mg/dl) ( ) ( ) 0.4 LDL (mg/dl) ( ) ( ) 0.1 C-reactive protein (mg/l) ( ) ( ) 0.4 Duration of AF (months) ( ) ( ) 0.4 Longest episode of AF (hours) ( ) ( ) 0.3 Paroxysmal AF, n (%) 23 (56) 18 (44) 0.7 AFSS - Episode frequency ( ) ( ) 0.4 AFSS - Episode duration ( ) ( ) 0.5 AFSS - Episode severity ( ) ( ) 0.3 AFSS - Burden ( ) ( ) 0.7 AFSS - symptom severity subscale ( ) ( ) 0.6 No. antiarrhythmic drugs, n (%) (33) 2 (67) 1 12 (55) 10 (45) 2 10 (62.5) 6 (37.5) No. antihypertensive drugs, n (%) (37.5) 5 (62.5) 1 10 (56) 8 (44) 2 5 (50) 5 (50) 3 3 (100) 0 (0) 4 2 (100) 0 (0) Tobacco use, n (%) 1.0 Never 15 (58) 11 (42) Current 1 (50) 1 (50) Reformed 7 (54) 6 (46)
14 etable 6: Descriptive comparison of control and intervention subjects who dropped out. (Continued) CPAP use, n (%) Yes 1 (50) 1 (50) Characteristic Retained Drop-outs (n=109) (n=41) No 22 (59) 15 (41) 1.0 P-value OSA, n (%) 0.4 Absent 2 (100) 0 (0) Mild 5 (45) 6 (55) Moderate 8 (73) 3 (27) Severe 3 (43) 4 (57) Hypertension, n (%) 1.0 Absent 3 (50) 3 (50) Present 20 (57) 15 (43) SBP (mmhg) ( ) ( ) 1.0 DBP (mmhg) (83-89) (79-86) 0.07 Diabetes, n (%) 0.08 Absent 20 (65) 11 (35) Present 3 (30) 7 (70) Metformin use, n (%) 1.0 Absent 22 (55) 18 (45) Present 1 (100) 0 (0) Oral hypoglycemic use, n (%) 1.0 Absent 22 (55) 18 (45) Present 1 (100) 0 (0) Alcohol consumption, n (%) Absent 17 (53) 15 (47) Present 6 (67) 3 (33) Lipid-lowering therapy use, n (%) Absent 18 (56) 14 (44) Present 5 (56) 4 (44) etable 6: Shown is descriptive data comparing the control and treatment arms in the drop-outs. P values were derived from Fisher s exact test or analysis of variance. The groups were well matched with respect to all variables; however there was a trend towards significance for; diastolic blood pressure (greater in the control group arm as compared to the intervention arm) and the presence of diabetes mellitus (greater in the control population as compared to the intervention population). BMI body mass index, BSA body surface area, HDL high density lipoprotein, LDL low density lipoprotein, AFSS Atrial Fibrillation Severity Score, CPAP continuous positive airways pressure, OSA obstructive sleep apnea, SBP systolic blood pressure, DBP diastolic blood pressure. Continuous data is shown as mean and 95% CI. Proportional data is shown as number (No.) and %
15 Propensity score analysis In order to account for baseline imbalances, a propensity score for treatment allocation group was generated based on the following covariates: age, gender, baseline body-mass index, baseline alcohol and tobacco use, hypertension, diabetes, hypercholesterolemia, obstructive sleep apnea, number of antiarrhythmic and antihypertensive agents used, left atrial area, the occurrence of any AF on baseline Holter monitoring and the cumulative duration of AF on baseline Holter monitoring. Mixed effects models were then repeated with adjustment for this propensity score. We generated a propensity score for each participant based on the following variables: age, gender, baseline body-mass index, baseline alcohol and tobacco use, hypertension, diabetes, hypercholesterolemia, obstructive sleep apnea, number of antiarrhythmic and antihypertensive agents used, left atrial area, the occurrence of any AF on baseline Holter monitoring and the cumulative duration of AF on baseline Holter monitoring. We then repeated all analyses adjusting for this propensity score. The adjustment did not alter the significance of our findings favoring the treatment group. All group-time interaction term p-values remained (efigure 4 and efigure 5 below).
16 efigure 4. Propensity Score Analysis: Propensity Score Adjusted Outcomes, I: AFSS Symptom Burden Score and AFSS Symptom Severity Score efigure 4: Propensity score adjusted outcomes I: AFSS symptom burden score and AFSS symptom severity score. The following variables were adjusted for; age, gender, baseline body-mass index, baseline alcohol and tobacco use, hypertension, diabetes, hypercholesterolemia, obstructive sleep apnea, number of antiarrhythmic and antihypertensive agents used, left atrial area, the occurrence of any AF on baseline Holter monitoring and the cumulative duration of AF on baseline Holter monitoring. AFSS Atrial fibrillation severity score.
17 efigure 5. Propensity Score Analysis: Propensity Score Adjusted Outcomes, II: Secondary (Holter Data) and Post Hoc (AFSS) Analysis efigure 5: Propensity score adjusted outcomes II: propensity score adjusted analysis for the secondary outcome of cumulative AF duration (on 7-day Holter recordings) and the secondary AFSS analyses of AF symptom frequency (AFSS1), AF symptom duration (AFSS2) and AF global episode symptom severity (AFSS3). The following variables were adjusted for; age, gender, baseline body-mass index, baseline alcohol and tobacco use, hypertension, diabetes, hypercholesterolemia, obstructive sleep apnea, number of antiarrhythmic and antihypertensive agents used, left atrial area, the occurrence of any AF on baseline Holter monitoring and the cumulative duration of AF on baseline Holter monitoring. AFSS Atrial fibrillation severity score.
18 149 etable 7. Adverse Events Documented During the Study Stage Event Comments (months) Control Intervention severe anemia (Hemoglobin <90 g/dl) 1 acute coronary syndrome 1 progressive acute decompensated cardiac failure 1 thyrotoxicosis 2 thyrotoxicosis 1 acute coronary syndrome 1 severe depression 1 severe refractory hypertension 1 malignancy 3 gastrointestinal symptoms 2 unstable INR Due to diabetic renal disease Managed invasively Secondary to atrial tachyarrhythmia cardiomyopathy All de-novo biochemical and clinical. Assumed due to amiodarone. Required prolonged corticosteroids and carbimazole Recurrence of ovarian cancer (>5 years prior) 1 bloating, 1 diarrhea and 1 constipation. All failed conservative management 1 elevated INR (>9) required IV vitamin K, 1 unable to achieve therapeutic INR due to dietary interference Managed invasively Known pre-existing stable treated depression Pre-existing hypertension. Persistent readings >190/110 mmhg despite multiple agents. Referred for investigation of secondary causes 1 malignancy Renal cell 1 troponin negative chest pain 1 progressive acute decompensated cardiac failure Stable coronary artery disease. Cardiorespiratory causes excluded Progression of chronic ischemic coronary artery disease. Managed medically.
19 152 efigure 6. Sensitivity Analyses efigure 6: Depicted are the effects of varying the value taken by missing observations on regression coefficients for the relationship between group allocation (treatment versus control) and change in A) AFSS frequency (afss1), B) AFSS duration (afss2), C) AFSS episode severity (afss3), D) AFSS burden (afss_bdn), E) AFSS symptom severity subscale (afss_sympt). Also shown is the effect of varying the informatively missing odds ratios from 0 to 1 on the risk of having any AF on 7-day Holter monitor at final follow-up (F). 161
20 efigure 7. Imputation Analysis (I) for Subjects Undergoing AF Ablation (Return-to- Method) efigure 7: Imputation analysis using the return to baseline symptom score method (moderately conservative approach). Top panel shows primary outcomes (AFSS symptom burden and AFSS symptom severity). Bottom panel shows secondary outcomes (ambulatory rhythm monitoring). The AFSS1, 2 and 3 refer to the secondary analyses; AFSS symptom frequency score, AFSS symptom duration score and AFSS global episode symptom severity score, respectively. AFSS Atrial fibrillation severity score. 171
21 efigure 8. Imputation Analysis (II) for Subjects Undergoing AF Ablation (Last Observation Method) efigure 8: Imputation analysis using the last measured symptom score method (least conservative approach). Above figure shows the last symptom score method for imputation analysis for the primary outcomes and the secondary analyses of AFSS symptom frequency (AFSS1), AFSS symptom duration (AFSS2) and AFSS global episode severity (AFSS3). AFSS Atrial fibrillation severity score.
22 180 efigure 9. Atrial Fibrillation Severity Score (AFSS) Algorithm efigure 9: Atrial Fibrillation Severity Score algorithm reproduced with permission from Professor Paul Dorian of St Michael s Hospital, The University of Toronto. 186
23 187 efigure 10. Mixed-Effects Models Analysis of Residuals I and II efigure 10: Hanging rootograms displaying residuals of the mixed-effects models for the primary outcomes (AFSS symptom burden and AFSS symptoms severity) and secondary outcomes (cumulative arrhythmia on 7-day ambulatory rhythm monitor and AFSS1 [AFSS symptom frequency], AFSS2 [AFSS symptom duration] and AFSS3 [AFSS global symptom severity score]).
Supplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationSupplementary Online Content
Supplementary Online Content Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line Treatment of Paroxysmal Atrial Fibrillation (RAAFT-2): a randomzied clinical
More informationIndividual Study Table Referring to Item of the Submission: Volume: Page:
2.0 Synopsis Name of Company: Abbott Laboratories Name of Study Drug: Meridia Name of Active Ingredient: Sibutramine hydrochloride monohydrate Individual Study Table Referring to Item of the Submission:
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationSupplementary Online Content
Supplementary Online Content McEvoy JW, Chen Y, Ndumele CE, et al. Six-year change in high-sensitivity cardiac troponin T and risk of subsequent coronary heart disease, heart failure, and death. JAMA Cardiol.
More informationCARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES
CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES C. Liakos, 1 G. Vyssoulis, 1 E. Karpanou, 2 S-M. Kyvelou, 1 V. Tzamou, 1 A. Michaelides, 1 A. Triantafyllou, 1 P. Spanos, 1 C. Stefanadis
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationIdentification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study
Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationTreatment strategy decision tree
strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent
More informationCoronary artery disease (CAD) risk factors
Background Coronary artery disease (CAD) risk factors CAD Risk factors Hypertension Insulin resistance /diabetes Dyslipidemia Smoking /Obesity Male gender/ Old age Atherosclerosis Arterial stiffness precedes
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More informationSupplementary Online Content
Supplementary Online Content Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous electrocardiographic monitoring patch on detection of undiagnosed atrial fibrillation
More information4. resisted training ** OR resistance training * OR resisted exercise ** OR resistance exercise ** OR strength training ** OR strength exercise **
Supplementary Table 1. Search strategy (up to January 10 th 2015). MEDLINE Result: 253 studies 1. clinical trial ** OR controlled trial ** OR randomized controlled trial * OR randomised controlled trial
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationProf. Samir Morcos Rafla Alexandria Univ. Cardiology Dept.
Obesity as a risk factor for Atrial Fibrillation Prof. Samir Morcos Rafla Alexandria Univ. Cardiology Dept. CardioAlex 2010 smrafla@hotmail.com 1 Obesity has reached epidemic proportions in the United
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationSupplementary Online Content
Supplementary Online Content Sigal RJ, Alberga AS, Goldfield GS, et al. Effects of aerobic training, resistance training, or both on percentage body fat and cardiometabolic risk markers in obese adolescents:
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationSupplementary Online Content
Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.
More informationConsensus document: Screening and Prevention of Atrial Fibrillation
Consensus document: Screening and Prevention of Atrial Fibrillation Yong-Seog Oh, M.D.,Ph.D. Division of Cardiology, Department of Internal Medicine, Seoul St. Mary s Hospital, College of Medicine, The
More informationProcess Measure: Screening for Adult Obstructive Sleep Apnea
Process Measure: Screening for Adult Obstructive Sleep Apnea Measure Description Description Type of Measure All patients aged 18 years and older at high risk for obstructive sleep apnea (OSA) with documentation
More informationSupplementary Online Content
Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw
More informationHigh Risk OSA n = 5,359
Table S1 Prevalence of atrial fibrillation (AF) identified using different methods in participants with high and low risk obstructive sleep apnea (). High Risk n = 5,359 Low Risk n = 14,992 SR-AF (%) 467
More informationThe RealiseAF registry:
The RealiseAF registry: An International, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of AF patients initial results PG.Steg on behalf
More informationAF Today: W. For the majority of patients with atrial. are the Options? Chris Case
AF Today: W hat are the Options? Management strategies for patients with atrial fibrillation should depend on the individual patient. Treatment with medications seems adequate for most patients with atrial
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationSupplementary Online Content
Supplementary Online Content Xu X, Qin X, Li Y, et al. Efficacy of folic acid therapy on the progression of chronic kidney disease: the Renal Substudy of the China Stroke Primary Prevention Trial. JAMA
More informationScreening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016
Juniata College Screening Results Juniata College Screening Results October 11, 2016 & October 12, 2016 JUNIATA COLLEGE The J.C. Blair Hospital CARES team screened 55 Juniata College employees on October
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationRebuttal. Jerónimo Farré MD 2010
Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF
More informationComorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Online Content
Supplementary Online Content Pedersen SB, Langsted A, Nordestgaard BG. Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med. Published online November 7, 2016.
More informationSupplementary Online Content
Supplementary Online Content Verma A, Champagne J, Sapp J, et al. Asymptomatic episodes of atrial fibrillation before and after catheter ablation: a prospective, multicenter study. JAMA Intern Med. Published
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Bhakta N, Liu Q, Yeo F, et al. Cumulative burden
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu Indicator area: Pulse rhythm assessment for AF Indicator: NM146 Date: June 2017 Introduction There is evidence
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationCommon Codes for ICD-10
Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified
More informationCardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh
"Insight Heart" is also available at www.squarepharma.com.bd Cardiovascular Risk Factors: Distribution and Prevalence in a Rural Population of Bangladesh Coronary heart disease has been emerging as an
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationEpidemiologic Measure of Association
Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2
More informationCatheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) Trial
Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) Trial Douglas L. Packer MD, Kerry L. Lee PhD, Daniel B. Mark MD, MPH, Richard A. Robb PhD for the CABANA Investigators Mayo
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationAtrial fibrillation. Causative factors of AF. Untreated/inadequately treated hypertension
Earn 3 CPD Points online Atrial fibrillation 30 years on Review of atrial fibrillation and the lessons of 30 years Professor Paul Dorian Division of Cardiology and Division of Clinical Pharmacology University
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationKnow Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
More informationPage 1. Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion. Atrial fibrillation: Scope of the problem
Current Trends in the Management of Atrial Fibrillation: Left Atrial Appendage Occlusion Benjamin A. D Souza, MD, FACC, FHRS Assistant Professor of Clinical Medicine Penn Presbyterian Medical Center Cardiac
More informationApelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure CI Liakos, 1 EA Sanidas, 1 DN Perrea, 1 V Gennimata, 1 V Chantziara, 1 CA Grassos, 2 N-A Viniou, 1 JD Barbetseas,
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationSamer Nasr, M.D. Mount Lebanon Hospital.
Samer Nasr, M.D. Mount Lebanon Hospital. Lone atrial fibrillation: Younger than 60 years old. No clinical or echo evidence of cardiopulmonary disease. Favorable prognosis. Thromboembolism usually not
More informationFigure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
More informationTRIple pill vs. Usual care Management for Patients with mild-to-moderate Hypertension
TRIple pill vs. Usual care Management for Patients with mild-to-moderate Hypertension The TRIUMPH study Dr Ruth Webster, PhD, MBBS, MIPH, BMedSc Global control rates for hypertension BP < 140/90 among
More informationGOALS. Obstructive Sleep Apnea and Cardiovascular Disease (OVERVIEW) FINANCIAL DISCLOSURE 2/1/2017
Obstructive Sleep Apnea and Cardiovascular Disease (OVERVIEW) 19th Annual Topics in Cardiovascular Care Steven Khov, DO, FAAP Pulmonary Associates of Lancaster, Ltd February 3, 2017 skhov2@lghealth.org
More informationDr. Dermot Phelan MB BCh BAO PhD European Society of Cardiology 2012
Relative Apical Sparing of Longitudinal Strain Using 2- Dimensional Speckle-Tracking Echocardiography is Both Sensitive and Specific for the Diagnosis of Cardiac Amyloidosis. Dr. Dermot Phelan MB BCh BAO
More informationStephen G. Worthley 1, Gerard T. Wilkins 2, Mark W. Webster 3,Joseph K. Montarello 1, Paul T. Antonis 4, Robert J. Whitbourn 5, Roderic J.
Six Month Results of First-in-Human Sympathetic Renal Artery Denervation Using a Next Generation Multi-Electrode Renal Artery Denervation System in Patients with Drug-Resistant Hypertension Stephen G.
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationMetabolic Syndrome Across the Life Cycle - Adolescent. Joy Friedman MD
Metabolic Syndrome Across the Life Cycle - Adolescent Joy Friedman MD Disclosures I have no actual or potential conflict of interest in relation to this program or presentation. I will mention off-label
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More information1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy. anticoagulation can be continued,
Experts Answering Your Questions Anticoagulating a high-risk cardiac patient 1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy for minor surgical
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationThe importance of follow-up after a cardiac event: CARDIAC REHABILITATION. Dr. Guy Letcher
The importance of follow-up after a cardiac event: CARDIAC REHABILITATION Dr. Guy Letcher The National Medicare Experience Mortality After Angioplasty 225,915 patients Mortality After Bypass Surgery 357,885
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationCandesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients
1/5 This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
More informationFabrice Czarnecki, M.D., M.A., M.P.H., FACOEM I have no disclosures to make.
Maryland College of Occupational and Environmental Medicine April 2014 Fabrice Czarnecki, M.D., M.A., M.P.H., FACOEM fczarnecki@gablesgroup.com I have no disclosures to make. Guidelines 2006: Joint Task
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More information2/11/2017. Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox. Disclosures. Carl J. Lavie, MD, FACC, FACP, FCCP
Weighing the Heavy Cardiovascular Burden of Obesity and the Obesity Paradox Carl J. Lavie, MD, FACC, FACP, FCCP Professor of Medicine Medical Director, Cardiac Rehabilitation and Preventive Cardiology
More informationHAS-BLED. Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest
HAS-BLED Ron Pisters, MD Maastricht University Medical Centre (NL) No conflict of interest r.pisters@mumc.nl Background major bleeding risk High stroke risk frequently warrants use of oral anticoagulation
More informationRisk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication
41 Research Article Risk Assessment of developing type 2 diabetes mellitus in patient on antihypertensive medication Amarjeet Singh*, Sudeep bhardwaj, Ashutosh aggarwal Department of Pharmacology, Seth
More informationSupplementary Online Content
Supplementary Online Content Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autistic spectrum disorder:
More informationSupplementary Online Content. Mozaffarian D, Marchioli R, Macchia A, et al; for the OPERA Investigators. Fish oil and
Supplementary Online Content Mozaffarian D, Marchioli R, Macchia A, et al; for the OPERA Investigators. Fish oil and postoperative atrial fibrillation: The Omega-3 Fatty Acids for Prevention of POst-operative
More informationPREVALENCE OF AND FACTORS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA IN A COHORT OF ADULTS WITH LONG DURATION TYPE 1 DIABETES MELLITUS.
PREVALENCE OF AND FACTORS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA IN A COHORT OF ADULTS WITH LONG DURATION TYPE 1 DIABETES MELLITUS by Hristina Denić BS in Nursing, Indiana University of Pennsylvania,
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationCardiovascular Diseases in CKD
1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9
More informationMy Patient Needs a Stress Test
My Patient Needs a Stress Test Amy S. Burhanna,, MD, FACC Coastal Cardiology Cape May Court House, New Jersey Absolute and relative contraindications to exercise testing Absolute Acute myocardial infarction
More informationAF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
More informationA CASE REPORT AND LITERATURE REVIEW ON MYOCARDIAL INFARCTION WITH NORMAL CORONARY ARTERIES
A CASE REPORT AND LITERATURE REVIEW ON MYOCARDIAL INFARCTION WITH NORMAL CORONARY ARTERIES Niyamtullah Musalman 1*, Lijun Jin 2 and Farhan Khan 3 *12 Department of Cardiology, Yangtze Medical University
More informationACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter
ACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task
More information